AZ Alma Eeklo
Immunohistochemistry (IHC) is one of the most commonly used research tools in anatomic pathology laboratories. It is widely used to purchase diagnostic and prognostic information and also to follow-up the treatments. To obtain optimal results of IHC tests, the laboratories must validate the immunohistochemistry assays and the antibodies, before those are placed into clinical service. Hepatocyte specific antigen and Glypican 3 are being used for detection of hepatocellular carcinoma (HCC) and for identification of metastases of HCC-origin in formalin-fixed, paraffin embedded (FFPE) tissue sections. Those antigen-markers can be detected by immunohistochemical stainings with the Hep-par 1 and Glypican 3 antibodies. The purpose of this study is to validate Hep-par 1 and Glypican 3 using the staining protocols of Nordic immunohistochemical Quality Control (NordiQC).
This validation procedure includes the IHC-staining of multiblocks, containing punch specimens of positive and negative control tissues. The accuracy of the staining was evaluated by comparing the obtained results to the results indicted by NordiQC. The precision of the test was also established by defining the inter-run and the intra-run precision. After the evaluation of the results of the multiblock stainings and after validation of both antibodies, several adjustments have been made to the NordiQC protocol. The purpose of this adjustments was to obtain the same staining results with use of less antibodies.
Both Hep-par 1 and Glypican 3 perform an optimal staining results of FFPE tissue sections with the NordiQC staining protocol and are validated. Changes to the original protocol did not delivered better results.